Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Rheumatoid Arthritis, Plaque Psoriasis
Interventions
Etanercept via Autoinjector A, Etanercept via Autoinjector B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 25 more
Conditions
Seizures
Interventions
Midazolam
Drug
Lead sponsor
U.S. Army Office of the Surgeon General
Federal
Eligibility
18 Years to 54 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Huntsville, Alabama • Centennial, Colorado • Daytona Beach, Florida + 10 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100
Conditions
Healthy
Interventions
LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
Biological · Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Conditions
Healthy Adult Participants
Interventions
Autoinjector, Vial and syringe
Combination Product · Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Conditions
Thyroid Eye Disease
Interventions
VRDN-003, Autoinjector
Drug · Device
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Inglewood, California • Cape Coral, Florida • Kissimmee, Florida + 7 more
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Aventura, Florida • Palm Harbor, Florida • Sarasota, Florida + 9 more
Conditions
Giant Cell Arteritis
Interventions
Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder

NCT02669901
Conditions
Opiate Antagonist Overdose, Opioid-Related Disorders
Interventions
Naloxone Auto-Injector
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Multiple Sclerosis (MS)
Interventions
Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Conditions
Migraine
Interventions
Erenumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
42
States / cities
Huntsville, Alabama • Phoenix, Arizona • Fullerton, California + 38 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Galcanezumab in Healthy Participants.

NCT02836613
Conditions
Healthy
Interventions
Galcanezumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Completed Phase 3 Interventional Results available

Tezepelumab Home Use Study

NCT03968978
Conditions
Asthma
Interventions
Tezepelumab (APFS), Tezepelumab (AI)
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Hoover, Alabama • Gilbert, Arizona • Northridge, California + 12 more
Completed Phase 2 Interventional Results available

Evolocumab in Patients With Acute MI

NCT04082442
Conditions
Acute Coronary Syndrome
Interventions
Evolocumab, Placebos
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Multiple Sclerosis
Interventions
Interferon-beta-1b (BETASERON, BAY 86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Whippany, New Jersey
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Conditions
Opioid Overdose
Interventions
Nalmefene HCl injection, Naloxone HCl intranasal
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Atopic Dermatitis
Interventions
Tralokinumab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 24 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector, Placebo Liquid Auto-injector, Placebo Lyophilized DCC Pen injector
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Remternetug (LY3372993) in Healthy Participants

NCT07056309
Conditions
Healthy
Interventions
Remternetug (Test), Remternetug (Reference)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas
Completed Phase 3 Interventional Results available

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
Drug · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California